A PPARγ agonist (EC50 = ~ 500-600 nM for both human and murine PPARγ); selective for PPARγ over PPARα exhibiting low level activation of PPARα at 1 μM and 5.4-fold activation at a concentration of 10 μM; reduces hyperglycemia, hyperlipidemia, and hyperinsulinemia in a dose-dependent manner in male Wistar fatty rats from 0.3-3 mg/kg; reduces the number of lesions in a TRAP model; decreases production of neuroinflammatory cytokines and reduces immobility in the forced swim and tail suspension tests in a mouse model of chronic mild stress at 2.5 mg/kg,